FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1857024522> ?p ?o ?g. }

• W1857024522 endingPage "7674" @default.
• W1857024522 startingPage "7657" @default.
• W1857024522 abstract "// Marta Pojo 1, 2 , Céline S. Gonçalves 1, 2 , Ana Xavier-Magalhães 1, 2 , Ana Isabel Oliveira 1, 2 , Tiago Gonçalves 1, 2 , Sara Correia 3 , Ana J. Rodrigues 1, 2 , Sandra Costa 1, 2 , Luísa Pinto 1, 2 , Afonso A. Pinto 4 , José M. Lopes 5, 6, 7 , Rui M. Reis 1, 2, 8 , Miguel Rocha 3 , Nuno Sousa 1, 2 , Bruno M. Costa 1, 2 1 Life and Health Sciences Research Institute (ICVS), School of Health Sciences, University of Minho, Campus de Gualtar 4710–057 Braga, Portugal 2 ICVS/3B's—PT Government Associate Laboratory, Braga/Guimarães, Campus de Gualtar 4710–057 Braga, Portugal 3 Centre of Biological Engineering/Department of Informatics, University of Minho, Campus de Gualtar 4710–057 Braga, Portugal 4 Department of Neurosurgery, Hospital de Braga, Sete Fontes, 4710–243 São Victor, Braga, Portugal 5 Department of Pathology, Hospital S. João, Alameda Professor Hernâni Monteiro, 4200–319 Porto, Portugal 6 Institute of Molecular Pathology and Immunology at the University of Porto (IPATIMUP), Rua Dr. Roberto Frias s/n 4200–465 Porto, Portugal 7 Medical Faculty, University of Porto, Alameda Professor Hernâni Monteiro, 4200–319 Porto, Portugal 8 Barretos Cancer Hospital, Molecular Oncology Research Center, Rua Antenor Duarte Vilela, 1331-Doutor Paulo Prata, Barretos–SP, 14780–000, Brasil Correspondence to: Bruno M. Costa, e-mail: bfmcosta@ecsaude.uminho.pt Keywords: Glioblastoma, prognosis, oncogene, temozolomide, HOXA9 Received: September 22, 2014      Accepted: January 16, 2015      Published: February 20, 2015 ABSTRACT Glioblastoma is the most malignant brain tumor, exhibiting remarkable resistance to treatment. Here we investigated the oncogenic potential of HOXA9 in gliomagenesis, the molecular and cellular mechanisms by which HOXA9 renders glioblastoma more aggressive, and how HOXA9 affects response to chemotherapy and survival. The prognostic value of HOXA9 in glioblastoma patients was validated in two large datasets from TCGA and Rembrandt, where high HOXA9 levels were associated with shorter survival. Transcriptomic analyses identified novel HOXA9-target genes with key roles in cancer-related processes, including cell proliferation, DNA repair, and stem cell maintenance. Functional studies with HOXA9 -overexpressing and HOXA9 -silenced glioblastoma cell models revealed that HOXA9 promotes cell viability, stemness and invasion, and inhibits apoptosis. Additionally, HOXA9 promoted the malignant transformation of human immortalized astrocytes in an orthotopic in vivo model, and caused tumor-associated death. HOXA9 also mediated resistance to temozolomide treatment in vitro and in vivo via upregulation of BCL2. Importantly, the pharmacological inhibition of BCL2 with the BH3 mimetic ABT-737 reverted temozolomide resistance in HOXA9-positive cells. These data establish HOXA9 as a driver of glioma initiation, aggressiveness and resistance to therapy. In the future, the combination of BH3 mimetics with temozolomide should be further explored as an alternative treatment for glioblastoma." @default.
• W1857024522 created "2016-06-24" @default.
• W1857024522 creator A5001815948 @default.
• W1857024522 creator A5020683956 @default.
• W1857024522 creator A5021306664 @default.
• W1857024522 creator A5030104442 @default.
• W1857024522 creator A5031152359 @default.
• W1857024522 creator A5035432368 @default.
• W1857024522 creator A5039241075 @default.
• W1857024522 creator A5040524717 @default.
• W1857024522 creator A5063925293 @default.
• W1857024522 creator A5069300297 @default.
• W1857024522 creator A5073206843 @default.
• W1857024522 creator A5074665906 @default.
• W1857024522 creator A5081208807 @default.
• W1857024522 creator A5082133270 @default.
• W1857024522 creator A5083321170 @default.
• W1857024522 date "2015-02-20" @default.
• W1857024522 modified "2023-09-29" @default.
• W1857024522 title "A transcriptomic signature mediated by HOXA9 promotes human glioblastoma initiation, aggressiveness and resistance to temozolomide" @default.
• W1857024522 cites W1494864623 @default.
• W1857024522 cites W1563624749 @default.
• W1857024522 cites W1655331233 @default.
• W1857024522 cites W1976099423 @default.
• W1857024522 cites W1988141621 @default.
• W1857024522 cites W1989414412 @default.
• W1857024522 cites W1992362560 @default.
• W1857024522 cites W1994648009 @default.
• W1857024522 cites W2002772045 @default.
• W1857024522 cites W2005412609 @default.
• W1857024522 cites W2012172048 @default.
• W1857024522 cites W2023261559 @default.
• W1857024522 cites W2025183726 @default.
• W1857024522 cites W2031610930 @default.
• W1857024522 cites W2035833975 @default.
• W1857024522 cites W2035912070 @default.
• W1857024522 cites W2043353204 @default.
• W1857024522 cites W2052609775 @default.
• W1857024522 cites W2058569154 @default.
• W1857024522 cites W2068032512 @default.
• W1857024522 cites W2072870454 @default.
• W1857024522 cites W2074439230 @default.
• W1857024522 cites W2085419794 @default.
• W1857024522 cites W2095518647 @default.
• W1857024522 cites W2095662532 @default.
• W1857024522 cites W2096287682 @default.
• W1857024522 cites W2097478662 @default.
• W1857024522 cites W2099023875 @default.
• W1857024522 cites W2105100844 @default.
• W1857024522 cites W2107277218 @default.
• W1857024522 cites W2108973415 @default.
• W1857024522 cites W2113729674 @default.
• W1857024522 cites W2113824734 @default.
• W1857024522 cites W2118217096 @default.
• W1857024522 cites W2118731052 @default.
• W1857024522 cites W2121604817 @default.
• W1857024522 cites W2121625674 @default.
• W1857024522 cites W2123151929 @default.
• W1857024522 cites W2123349002 @default.
• W1857024522 cites W2130410032 @default.
• W1857024522 cites W2133840181 @default.
• W1857024522 cites W2136346901 @default.
• W1857024522 cites W2142647376 @default.
• W1857024522 cites W2143665087 @default.
• W1857024522 cites W2150258648 @default.
• W1857024522 cites W2151057281 @default.
• W1857024522 cites W2157528884 @default.
• W1857024522 cites W2158681922 @default.
• W1857024522 cites W2158773950 @default.
• W1857024522 cites W2161289668 @default.
• W1857024522 cites W2165871546 @default.
• W1857024522 cites W2167650288 @default.
• W1857024522 cites W2172242534 @default.
• W1857024522 cites W2192080449 @default.
• W1857024522 doi "https://doi.org/10.18632/oncotarget.3150" @default.
• W1857024522 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4480707" @default.
• W1857024522 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25762636" @default.
• W1857024522 hasPublicationYear "2015" @default.
• W1857024522 type Work @default.
• W1857024522 sameAs 1857024522 @default.
• W1857024522 citedByCount "45" @default.
• W1857024522 countsByYear W18570245222015 @default.
• W1857024522 countsByYear W18570245222016 @default.
• W1857024522 countsByYear W18570245222017 @default.
• W1857024522 countsByYear W18570245222018 @default.
• W1857024522 countsByYear W18570245222019 @default.
• W1857024522 countsByYear W18570245222020 @default.
• W1857024522 countsByYear W18570245222021 @default.
• W1857024522 countsByYear W18570245222022 @default.
• W1857024522 countsByYear W18570245222023 @default.
• W1857024522 crossrefType "journal-article" @default.
• W1857024522 hasAuthorship W1857024522A5001815948 @default.
• W1857024522 hasAuthorship W1857024522A5020683956 @default.
• W1857024522 hasAuthorship W1857024522A5021306664 @default.
• W1857024522 hasAuthorship W1857024522A5030104442 @default.
• W1857024522 hasAuthorship W1857024522A5031152359 @default.
• W1857024522 hasAuthorship W1857024522A5035432368 @default.
• W1857024522 hasAuthorship W1857024522A5039241075 @default.

• next